Stockreport

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease ...

DHI Group, Inc.  (DHX) 
Last dhi group, inc. earnings: 2/5 04:15 pm Check Earnings Report
US:NYSE Investor Relations: dhigroupinc.com/investors/default.aspx
PDF Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Christopher A. Viehbacher , "Biogen") announced today that Eisai has completed the rolling su [Read more]